Introduction {#sec1-1}
============

Thoracotomy is recognised as one of the most painful surgical procedures \[[@ref1]\]. Studies have shown that high levels of acute postoperative pain are associated with an increase in the likelihood of chronic pain \[[@ref2]\]. The severity of acute postoperative pain has been linked to the development of persistent postoperative pain \[[@ref3]\].

Post-thoracotomy pain syndrome (PTPS) is a common condition; its prevalence has been reported to reach 80% \[[@ref4]\]. It is defined as pain that recurs or persists along a thoracotomy scar at least two months after the surgical procedure \[[@ref5]\].

In general, postoperative pain after thoracotomy is burning and stabbing pain and shares many features of neuropathic pain \[[@ref6]\]. It was found that tissue damage leads to sensitisation of dorsal horn neurons, which causes hyperalgesia or allodynia. This course may contribute to chronification of pain. Therefore, initiating analgesic treatment before tissue damage can reduce hyperexcitability of dorsal horn neurons and central sensitisation \[[@ref7]\]. Hence, drugs that reduce postoperative hyperalgesia and control acute postoperative pain may be of clinical interest \[[@ref8]\].

Pregabalin is one of these drugs that can reduce the excitability of the dorsal horn neurons. It is a γ-aminobutyric acid analogue that binds to α2-δ subunits of the voltage-gated calcium channels in the central nervous system \[[@ref9]\]. It was first introduced as a potent anticonvulsant and anxiolytic drug \[[@ref10]\]. Pregabalin is recommended as a first-line treatment for neuropathic pain conditions \[[@ref11]\]. Because of its ability to block presynaptic voltage-gated calcium channels implicated in central sensitisation, perioperative use of pregabalin could be valuable in preventing the development of chronic pain \[[@ref12]\], \[[@ref13]\]. It has been successfully used perioperatively for controlling neuropathic pain during knee and laparoscopic surgery; therefore, similar positive results are expected for intercostal neuralgia in post-thoracotomy pain \[[@ref14]\].

The purpose of this study was to investigate the safety and efficacy of perioperative administration of pregabalin to control intercostal neuralgia after thoracotomy.

Patients and Methods {#sec1-2}
====================

The study included 60 ASA physical status I and II patients between 25 and 60 years of age scheduled for elective open thoracotomy for thoracic oncologic surgeries. They were recruited from the National Cancer Institute, Cairo University from January 2017 to February 2018. The study was approved by the local ethical committee, and every patient provided an informed written consent to participate in the study.

Patients with renal insufficiency, history of congestive heart failure, major psychiatric disorder, body mass index \> 40 kg/m^2^, weight \< 50 kg, pre-existing chronic pain in proposed surgical area or elsewhere requiring chronic analgesic use, hypersensitivity to opioids, tumors extending into chest wall, previous ipsilateral thoracotomy, chest tube in situ at time of surgery, patients on anticonvulsants, patients planned for postoperative ventilation, or those who cannot use patient-controlled analgesia (PCA) were excluded from the study.

Preoperatively patients were instructed how to use a visual analogue scale (VAS) (0 = no pain, 10 = worst pain) to express pain and use of the PCA device. Patients were randomly allocated to one of two equal groups. Pregabalin Group received pregabalin capsules, 150 mg (Lyrica, Pfizer, Egypt) while the Control group received placebo capsules (multivitamin capsules). A treatment schedule in the two groups was one capsule one hour before thoracotomy, 12 hours following operation (day zero postoperative), and then twice a day for 5 postoperative days.

All patients were premedicated with midazolam 0.05 mg/kg IV 30 minutes before the surgical procedure. A crystalloid IV infusion was established, and the baseline means arterial blood pressure (MAP), heart rate (HR), and peripheral oxygen saturation (SO~2~) were recorded. Anaesthesia was induced with fentanyl 2 μg/kg and propofol 2 mg/kg and atracurium 0.5 mg/kg IV and maintained with sevoflurane (2-3 vol%) and fresh gas flow rate of 2 L/min in combination with 50% oxygen/air. After endotracheal intubation, lungs were mechanically ventilated to maintain the end-expiratory CO~2~ values between 32-36 mm Hg, then morphine 0.1 mg/kg was administered IV. With skin closure, the residual neuromuscular blockade was antagonised with IV neostigmine 0.04 mg/kg and atropine 0.02 mg/kg. Ondansetron 4 mg IV was given to all patients.

Patients were then transferred to the intensive care unit (ICU) to start using the PCA device for 5 days (Accufuser PLUS M5015L WOO YOUNG MEDICAL CO.LTD, Korea). The PCA device contained a volume of 300 ml (60 mg morphine + 60 mg ketorolac + 2 mg Garnitryl). The basal rate was 5.0 ml/hr, and bolus 1.0 ml (0.2 mg) with a lockout interval of 15 min (limit of 1.8 mg/hr) and total opioid consumption were recorded. The pain was assessed using a VAS score at 0, and after 4, 8, 12, 16, 20, and 24 hours. The mean of VAS at rest (VAS-R) and during a cough or with movement or cough (dynamic) (VAS-D) were recorded. The occurrence of postoperative side effects (confusion, dizziness, headache, dry mouth, nausea, vomiting, and pruritus were recorded at follow up intervals.

Assessment of the incidence of chronic post-thoracotomy pain syndrome and pain quality (neuropathic versus other) using Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) scale was done at 1, 2, and 3 months postoperatively. Patients who suffered from symptoms of neuropathic pain, allodynia or hyperalgesia at first month received pregabalin 150 mg BID and were reassessed at 2^nd^ and 3^rd^ month. The LANSS pain scale consists of five items that document self-reported pain symptoms and two items that document the findings of a simple clinical examination conducted by the healthcare professional to assess the presence of allodynia and pin-prick threshold \[[@ref15]\]. A LANSS score of 12 or more is an indication of chronic neuropathic pain; allodynia (assessed by gentle rubbing of the operated site by a piece of cotton) and hyperalgesia (gently applied pressure from the fingertip).

Statistical Analysis {#sec2-1}
--------------------

Statistical Analysis was performed using SPSS 15.0 for Windows. Numerical data were expressed as mean and standard deviation or median and range as appropriate. Qualitative data were expressed as frequency and percentage. Chi-square test (Fisher's exact test) was used to examine the relation between qualitative variables. For quantitative data, a comparison between two groups was made using independent sample t-test or Mann-Whitney test. A *p*-value of \< 0.05 was accepted as statistically significant.

Results {#sec1-3}
=======

Demographic data, duration of anaesthesia and surgery were comparable between groups ([Table 1](#T1){ref-type="table"}).

###### 

Demographic data

  Variables                          Pregabalin (n = 30)   Control (n = 30)   p value
  ---------------------------------- --------------------- ------------------ ---------
  Age (years)                        46.9 ± 10.1           41.0 ± 14.5        0.072
  Weight (kg)                        83.1 ± 9.9            77.1 ± 15.5        0.078
  Height (cm)                        176 ± 9               173 ± 11           0.246
  Gender (M/F)                       22/8                  21/9               1.0
  Duration of surgery (minutes)      188 ± 25              178 ± 10           0.066
  Duration of anesthesia (minutes)   220 ± 28              211 ± 11           0.910
  Type of surgery                                                             
  Lobectomy                          9                     3                  0.117
  Pneumonectomy                      11                    17                 
  Pleurectomy                        10                    10                 

Data are expressed as mean ± SD (standard deviation), or number as appropriate; *P* value \< 0.05 is considered significant; There were no statistical differences among groups.

VAS-R and VAS-D were significantly lower in Pregabalin group at 0, 6, 18 and 24 hours but were comparable between groups at 12 hours ([Table 2](#T2){ref-type="table"}).

###### 

VAS-R and VAS-D. Data are expressed as mean ± SD

             Pregabalin (n = 30)   Control (n = 30)   *p* value                               
  ---------- --------------------- ------------------ --------------------------------------- ---------------------------------------
  0 hour     VAS-R                 2.9 ± 0.7          3.5 ± 1.0                               0.022[\*](#t2f1){ref-type="table-fn"}
  VAS-D      6.0 ± 0.7             6.6 ± 1.0          0.016[\*](#t2f1){ref-type="table-fn"}   
  6 hours    VAS-R                 3.3 ± 0.9          3.8 ± 0.7                               0.042[\*](#t2f1){ref-type="table-fn"}
  VAS-D      4.4 ± 0.9             5.0 ± 0.7          0.023[\*](#t2f1){ref-type="table-fn"}   
  12 hours   VAS-R                 2.6 ± 0.8          3.0 ± 0.9                               0.125
  VAS-D      3.5 ± 0.8             3.9 ± 0.9          0.209                                   
  18 hours   VAS-R                 2.1 ± 0.6          2.6 ± 0.8                               0.022[\*](#t2f1){ref-type="table-fn"}
  VAS-D      3.3 ± 0.7             3.8 ± 0.9          0.020[\*](#t2f1){ref-type="table-fn"}   
  24 hours   VAS-R                 1.6 ± 0.6          2.0 ± 0.6                               0.037[\*](#t2f1){ref-type="table-fn"}
  VAS-D      3.1 ± 0.7             3.5 ± 0.8          0.039[\*](#t2f1){ref-type="table-fn"}   

Data are expressed as mean ± SD (standard deviation); VAS-R = visual analogue score at rest; VAS-D = visual analogue score dynamic (during movement);

*P* value \< 0.05 is considered significant.

The mean VAS-R and VAS-D during 24 hours on days 1, 2, 3 and 4 were significantly lower in Pregabalin group. There was no significant difference between groups in days 5 and 6 ([Table 3](#T3){ref-type="table"}).

###### 

Mean of VAS-R and VAS-D during postoperative days 1, 2, 3, 4, 5 and 6

          Pregabalin (n = 30)   Control (n = 30)   *p* value                               
  ------- --------------------- ------------------ --------------------------------------- ---------------------------------------
  Day 1   VAS-R                 2.1 ± 0.7          2.5 ± 0.6                               0.047[\*](#t3f1){ref-type="table-fn"}
  VAS-D   4.1 ± 1.0             4.8 ± 0.8          0.014[\*](#t3f1){ref-type="table-fn"}   
  Day 2   VAS-R                 2.0 ± 0.8          2.5 ± .8                                0.031[\*](#t3f1){ref-type="table-fn"}
  VAS-D   3.1 ± 1.0             3.8 ± 0.8          0.021[\*](#t3f1){ref-type="table-fn"}   
  Day 3   VAS-R                 1.4 ± 0.5          1.8 ± 0.6                               0.027[\*](#t3f1){ref-type="table-fn"}
  VAS-D   2.5 ± 0.5             2.9 ± 0.7          0.043[\*](#t3f1){ref-type="table-fn"}   
  Day 4   VAS-R                 2.4 ± 0.7          2.8 ± 0.8                               0.022[\*](#t3f1){ref-type="table-fn"}
  VAS-D   3.3 ± 0.7             3.7 ± 0.8          0.029[\*](#t3f1){ref-type="table-fn"}   
  Day 5   VAS-R                 2.8 ± 0.8          2.9 ± 0.8                               0.981
  VAS-D   3.6 ± 0.8             3.8 ± 0.6          0.509                                   
  Day 6   VAS-R                 1.8 ± 0.6          2.2 ± 1.1                               0.163
  VAS-D   3.0 ± 0.8             3.5 ± 1.2          0.197                                   

Data are expressed as mean ± SD (standard deviation); VAS-R = visual analogue score at rest; VAS-D = visual analogue score dynamic (during movement);

*P* value \< 0.05 is considered significant.

###### 

Total daily morphine consumption in (mg) with PCA device from day 0 to day 4 in the two studied groups

          Pregabalin (n=30)   Control (n=30)   *p* value
  ------- ------------------- ---------------- ---------------------------------------
  Day 1   34.8±2.2            35.9±1.3         0.028[\*](#t4f1){ref-type="table-fn"}
  Day 2   30.9±2.7            32.3±2.2         0.033[\*](#t4f1){ref-type="table-fn"}
  Day 3   28.3±2.2            29.6±2.0         0.022[\*](#t4f1){ref-type="table-fn"}
  Day 4   26.4±2.0            27.5±1.9         0.035[\*](#t4f1){ref-type="table-fn"}

Data are expressed as mean ± SD (standard deviation);

*P* value \< 0.05 is considered significant.

The frequency of neuropathic pain, allodynia, and hyperalgesia at the site of operation were significantly lower in Pregabalin group after 1, 2- and 3-months post-thoracotomy ([Table 5](#T5){ref-type="table"}).

###### 

The proportion of post-thoracotomy chronic pain after 1, 2 and 3 months

                     Pregabalin (n = 30)   Control (n = 30)   *p* value
  ------------------ --------------------- ------------------ ---------------------------------------
  Neuropathic pain                                            
  At 1 month         3 (10.0%)             11 (36.7%)         0.015[\*](#t5f1){ref-type="table-fn"}
  At 2 months        1 (3.3%)              8(26.7%)           0.011[\*](#t5f1){ref-type="table-fn"}
  At 3 months        0 (0.0%)              5 (16.7%)          0.052[\*](#t5f1){ref-type="table-fn"}
  Allodynia                                                   
  At 1 month         5 (16.7%)             13 (43.3%)         0.024[\*](#t5f1){ref-type="table-fn"}
  At 2 months        2 (6.7%)              9 (30.0%)          0.020[\*](#t5f1){ref-type="table-fn"}
  At 3 months        0 (0.0%)              6 (20.0%)          0.024[\*](#t5f1){ref-type="table-fn"}
  Hyperalgesia                                                
  At 1 month         3 (10.0%)             11 (36.7%)         0.015[\*](#t5f1){ref-type="table-fn"}
  At 2 months        2 (6.7%)              9 (30.0%)          0.020[\*](#t5f1){ref-type="table-fn"}
  At 3 months        0 (0.0%)              7 (23.3%)          0.011[\*](#t5f1){ref-type="table-fn"}

Data are expressed as number (proportion);

*P* value \< 0.05 is considered significant.

Adverse effects were comparable between groups ([Table 6](#T6){ref-type="table"}). No cases of respiratory depression were recorded.

###### 

Incidence of Adverse Effects

              Pregabalin (n=30)   Control (n=30)   *p* value
  ----------- ------------------- ---------------- -----------
  Confusion   2 (6.7%)            4 (13.3%)        0.671
  Dizziness   5 (16.7%)           8 (26.7%)        0.347
  Headache    3 (10.0%)           2 (6.7%)         1.000
  Dry Mouth   1 (3.3%)            2 (6.7%)         1.000
  Nausea      8 (26.7%)           3 (10.0%)        0.095
  Vomiting    3 (10.0%)           1 (3.3%)         0.612
  Pruritus    3 (10.0%)           1 (3.3%)         0.612

Data are expressed as number (proportion); \**P* value \< 0.05 is considered significant.

Discussion {#sec1-4}
==========

The results of this study demonstrated that perioperative administration of pregabalin reduced pain intensity and morphine consumption during the first postoperative 4 days in patients having oncologic surgery through a thoracotomy incision. The frequency of chronic neuropathic pain, allodynia and hyperalgesia was significantly reduced in pregabalin group one, two, and three months after surgery. The frequency of side effects like confusion, dizziness, headache, and dry mouth was not increased in the pregabalin group.

In this study, the first dose of pregabalin 150 mg is given 1 hour before surgery to provide analgesia immediately after surgery. The idea of the study was to test whether pregabalin will have better control of acute postoperative pain aiming at prevention of pain chronification \[[@ref16]\]. The proposed action of pregabalin was suppression of hyperexcitability of the dorsal horn neurons and neuroplastic changes after surgery. Pregabalin has predominantly inhibitory effect during the first 24 hours; then it has an excitatory effect for 5 days after surgery \[[@ref17]\]. The daily pregabalin dose of 300 mg used in this study was based on previous studies \[[@ref14]\], \[[@ref15]\].

In the current study, on postoperative day 0, the pain intensity was less in pregabalin group throughout the day. This can be contributed to the synergistic analgesic effect of pregabalin with morphine, which led to a decrease in opioid consumption in the first day. After that, pain intensity was lower in the pregabalin group from day 1 through day 4 with reduced total morphine consumption.

Previous studies reported similar results in different after different surgical procedures. Bornemann-Cimenti et al., \[[@ref7]\] found that the preoperative administration of 300 mg pregabalin in patients undergoing transperitoneal nephrectomy reduces postoperative opioid consumption by 33% within the first 48 h. In video-assisted thoracoscopic surgery, a single dose of pregabalin 150 mg preoperatively was effective in reducing the pain intensity and need for additional analgesic drugs \[[@ref19]\]. Another study reported adequate postoperative pain control after robot-assisted endoscopic thyroidectomy using one dose of 150 mg 1 h before surgery and another dose 12 hours after \[[@ref20]\]. Similar results were reported \[[@ref21]\].

In the current study, perioperative administration of pregabalin decreased the frequency of chronic neuropathic pain after one, two and three months after surgery. Similar results were obtained concerning allodynia and hyperalgesia in the pregabalin group.

By these findings, Fawzi and El-Tohamy found that perioperative pregabalin reduces the incidence of chronic post-thoracotomy pain at 3 and 6 months from 60 and 40% to 10 and 6.7%, respectively \[[@ref22]\].

On the contrary, Brulotte et al. concluded that pregabalin did not reduce the incidence of PTPS. However, among pregabalin users who developed PTPS, pain intensity was less marked, required significantly fewer analgesics, and presented significantly less neuropathic characteristics compared to patients in the placebo group 3 months after surgery \[[@ref13]\].

The limitation of our study is a relatively small sample size and short follow up, which is only three months. In conclusion, perioperative use of pregabalin reduces pain and opioid consumption during the acute postoperative period and the incidence of chronic pain at two and three months after thoracotomy.
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